GWPH - How GW Pharmaceuticals Blew Away Expectations With Its Q3 Results
You might think that GW Pharmaceuticals (NASDAQ: GWPH) has had a lot of bad news in 2020 if you looked only at its stock performance. That isn't the case, though. The company has won key regulatory approvals and delivered solid revenue growth -- at least so far this year.
GW's growth streak was put to the test when the company announced its third-quarter results before the market opened on Tuesday. And the cannabinoid-focused drugmaker passed that test with flying colors. Here are the highlights from GW's Q3 update.
Image source: Getty Images.
For further details see:
How GW Pharmaceuticals Blew Away Expectations With Its Q3 Results